These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 3485230)
21. Accumulation of a parkinsonism-inducing neurotoxin in melanin-bearing neurons: autoradiographic studies on 3H-MPTP. Lindquist NG; Lydén-Sokolowski A; Larsson BS Acta Pharmacol Toxicol (Copenh); 1986 Aug; 59(2):161-4. PubMed ID: 3490739 [No Abstract] [Full Text] [Related]
22. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
23. [Current aspects of the etiology of Parkinson disease]. Fuhr P Praxis (Bern 1994); 1997 Jan; 86(3):34-6. PubMed ID: 9045282 [No Abstract] [Full Text] [Related]
24. The MPTP tale: pathway to prevention of Parkinson's disease? Williams A; Waring R Br J Hosp Med; 1993 May 19-Jun 1; 49(10):716-9. PubMed ID: 8324592 [TBL] [Abstract][Full Text] [Related]
26. Effect of ascorbic acid on dopamine level in the mouse brain after intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Smiałek M; Bugera-Piecuch TE; Kosicka B Neuropatol Pol; 1987; 25(3):299-304. PubMed ID: 3502483 [No Abstract] [Full Text] [Related]
28. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147 [TBL] [Abstract][Full Text] [Related]
29. Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson's disease. Shahi GS; Moochhala SM; Lee EJ; Das NP Ann Acad Med Singap; 1989 Jan; 18(1):93-7. PubMed ID: 2785364 [TBL] [Abstract][Full Text] [Related]
30. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Javitch JA; Snyder SH Eur J Pharmacol; 1984 Nov; 106(2):455-6. PubMed ID: 6335692 [No Abstract] [Full Text] [Related]
31. [Pathogenic substances in Parkinson disease and new therapeutics considering the etiologic mechanism]. Nagatsu T Nihon Rinsho; 1988 Sep; 46(9):2086-97. PubMed ID: 2907356 [No Abstract] [Full Text] [Related]
32. MPTP: insights into the etiology of Parkinson's disease. Langston JW Eur Neurol; 1987; 26 Suppl 1():2-10. PubMed ID: 3556187 [TBL] [Abstract][Full Text] [Related]
33. Normal MPTP binding in parkinsonian substantial nigra: evidence for extraneuronal toxin conversion in human brain. Uhl GR; Javitch JA; Snyder SH Lancet; 1985 Apr; 1(8435):956-7. PubMed ID: 2859415 [TBL] [Abstract][Full Text] [Related]
34. Methyltetrahydro-beta-carbolines and Parkinson's disease. Ohkubo S; Hiraro T; Oka K Lancet; 1985 Jun; 1(8440):1272-3. PubMed ID: 2860467 [No Abstract] [Full Text] [Related]
35. The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders. Donaldson J Neurotoxicology; 1987; 8(3):451-62. PubMed ID: 3309736 [No Abstract] [Full Text] [Related]
39. Trichloroharmanes as potential endogenously formed inducers of Morbus Parkinson: synthesis, analytics, and first in vivo-investigations. Bringmann G; Friedrich H; Feineis D J Neural Transm Suppl; 1992; 38():15-26. PubMed ID: 1491246 [TBL] [Abstract][Full Text] [Related]